EGFR and head and neck neoplasm: The first human Phase 1/2 clinical trial of NIR-PIT using cetuximab-IR700 targeting EGFR in patients with inoperable recurrent head and neck tumours was successfully completed in 2017 (Mitsunaga et al., 2011).